TrialJAMA neurology2025

An Acetylcholine M1 Receptor-Positive Allosteric Modulator (TAK-071) in Parkinson Disease With Cognitive Impairment: A Phase 2 Randomized Clinical Trial.

Niraj M Shanbhag et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.